33 Réponse(s)

Légende : Essai en cours de recrutement = ; Essai en cours =

- ALLEMAGNE
- Berlin
- NOT YET IDENTIFIED - DE
- In vitro evaluation of allergic reactions in hemophilia B subjects who have exhibited a systemic allergic response after exposure to BeneFIX (Nonacog Alfa; recombinant Factor IX) (Phase IV) - DE - Terminated
- Not yet identified - DE
- Plus de détails
- ALLEMAGNE
- Berlin
- NOT YET IDENTIFIED - DE
- paradigm 2: A phase III multicentre, single-blind trial evaluating safety and efficacy, including pharmacokinetics, of NNC-0156-0000-0009 when used for treatment and prophylaxis of bleeding episodes in patients with Haemophilia B - DE
- Not yet identified - DE
- Plus de détails
- ALLEMAGNE
- Berlin
- NOT YET IDENTIFIED - DE
- A Phase II/III open-label, multicenter, safety and efficacy study of a recombinant coagulation Factor IX Albumin Fusion Protein (rIX-FP) in subjects with Hemophilia B - DE
- Not yet identified - DE
- Plus de détails
- BELGIQUE
- BRABANT WALLON
- LOUVAIN-LA-NEUVE
- Gait Evaluation in Haemophiliac Patients (observational).
- Pierre De Coubertin
- Institut d'Education Physique et Readaptation
- Plus de détails
- ESPAGNE
- Cataluña
- BARCELONA
- Recombinant Factor IX (BAX 326): A Phase 1/3, Prospective, Controlled, Multicenter Study Evaluating Pharmacokinetics, Efficacy, Safety and Immunogenicity in Previously Treated Patients With Severe or Moderately Severe Hemophilia B (completed)
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Plus de détails
- ESPAGNE
- Cataluña
- BARCELONA
- BAX 326 (Recombinant Factor IX): Evaluation of Safety, Immunogenicity, and Hemostatic Efficacy in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B - A Continuation Study - ES
- Hospital Universitari General Vall d'Hebron
- Unidad de Hemofilia
- Plus de détails
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- Efficacy and Safety of NNC 0078-0000-0007 in Treatment of Acute Bleeding Episodes in Patients With Congenital Haemophilia and Inhibitors (Phase III) - ES (completed)
- Not yet identified - ES
- Plus de détails
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase II/III Open-label, Multicenter, Safety and Efficacy Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Subjects With Hemophilia B - ES
- Not yet identified - ES
- Plus de détails
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
- Not yet identified - ES
- Plus de détails
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 During Surgical Procedures in Patients With Haemophilia B (Phase III) - ES
- Not yet identified - ES
- Plus de détails
- ESPAGNE
- Madrid
- NOT YET IDENTIFIED - ES
- Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B (Phase III) - ES
- Not yet identified - ES
- Plus de détails
- FRANCE
- ILE-DE-FRANCE
- PARIS
- Etude exploratoire multicentrique, multinationale randomisée, en double insu et en groupes parallèles ayant pour objectif d'évaluer la sécurité, la pharmacocinétique et la détermination de dose du rFVIIa (LA-rFVIIa) à action prolongée en traitement prophylactique chez des patients hémophiles A ou B avec inhibiteurs (Phase II).
- CHU Paris - Hôpital Necker - Enfants Malades
- Centre Régional de traitement de l'hémophilie François Josso
- Plus de détails
- FRANCE
- NORD-PAS-DE-CALAIS
- LILLE
- FEIBA NF: Une étude prospective, ouverte, randomisée, en parallèle visant à évaluer l'efficacité et l'innocuité d'un traitement prophylactique par rapport à un traitement à la demande chez des patients atteints d'hémophilie de type A ou B et présentant un titre élevé d'inhibiteurs (phase III).
- CHRU de Lille - Centre de biologie pathologie génétique
- Service Hématologie-Transfusion
- Plus de détails
- FRANCE
- RHONE-ALPES
- LYON
- B-LONG: Etude multicentrique en ouvert évaluant la sécurité d'emploi, la pharmacocinétique et l'efficacité de la protéine de fusion Fc-Facteur IX recombinant (rFIXFc) à action prolongée pour la prévention et le traitement des hémorragies chez des patients atteints d'hémophilie B sévère préalablement traités.
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Plus de détails
- FRANCE
- RHONE-ALPES
- LYON
- Étude de phase I/II/III de la pharmacocinétique et des résultats du facteur IX recombinant d'Inspiration, IB1001, chez des sujets atteints d'hémophilie B.
- CHRU Lyon - Hôpital Edouard Herriot
- Centre régional de traitement de l'hémophilie
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Evaluation in vitro des manifestations allergiques chez des sujets atteints d'hémophilie B ayant manifesté une réponse allergique systémique après une exposition à BeneFIX (Nonacog Alfa ; facteur IX recombinant) (Phase IV)
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - FR
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - FR
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - FR
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- A Phase 2a Study of Ataluren (PTC124) as an Oral Treatment for Nonsense-Mutation-Mediated Hemophilia A and B - FR
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- FEIBA NF: A prospective, open-label, randomized, parallel study to evaluate efficacy and safety of prophylactic versus on-demand treatment in subjects with hemophilia A or B and a high titer inhibitor - FR
- Not yet identified - FR
- Plus de détails
- FRANCE
- RHONE-ALPES
- NOT YET IDENTIFIED - FR
- Phase 1/2, Prospective, Dose-Escalation/Finding Study to Evaluate Pharmacokinetics and Immediate Tolerability of Recombinant Activated FVII (rFVIIa BI) in Patients with Hemophilia A or B and Inhibitors - FR
- Not yet identified - FR
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- FERRARA
- Gentamycin treatment of congenital coagulation factor VII or factor IX deficiency caused by nonsense mutations (phase II)
- Università degli Studi di Ferrara
- Laboratorio di Biologia Molecolare dell'Emostasi e Trombosi
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- FEIBA NF: A Prospective, Open-label, Randomized, Parallel Study to Evaluate the Efficacy and Safety of Prophylactic Versus On-Demand Treatment in Subjects With Hemophilia A or B and a High Titer Inhibitor (Phase III) - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 2: A Multi-centre, Single-blind Trial Evaluating Safety and Efficacy, including Pharmacokinetics, of NNC-0156-0000-0009 when used for Treatment and Prophylaxis of Bleeding Episodes in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 3: An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 4: Safety and Efficacy of NNC-0156-0000-0009 after Long-Term Exposure in Patients with Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II/III open-label, multicenter, safety and efficacy study of a recombinant coagulation Factor IX Albumin Fusion Protein (rIX-FP) in subjects with Hemophilia B - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- Paradigm 5: Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B - IT
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- An Open-Label, Multicenter, Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase II-III trial to evaluate the efficacy and safety of BAY86-6150
- NOT YET IDENTIFIED - IT
- Plus de détails
- ITALIE
- EMILIA ROMAGNA
- NOT YET IDENTIFIED - IT
- A Phase III Open-label, Multicenter, Pharmacokinetic, Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Previously Treated Children With Hemophilia B
- NOT YET IDENTIFIED - IT
- Plus de détails
- ROYAUME-UNI
- Greater London
- LONDON
- An open label dose-escalation study of a self complementary adeno-associated viral vector (scAAV2/8-LP1-hFIXCO) for gene therapy of haemophilia B (Phase I/II)
- University College London
- Department of Haematology
- Plus de détails

Le portail des maladies rares et des médicaments orphelins

Orphanet index

Menu principal :

Sous menu :

Chemin de navigation :

Recherche par maladie / gène

Autre(s) option(s)

33 Réponse(s)

Orphanet

Footer: